e-learning
resources
2020
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer
Clémence Legoupil, Didier Debieuvre, Aurelien Marabelle, Stefan Michiels, Raïssa Kapso, Benjamin Besse, Julia Bonastre
Source:
ERJ Open Res, 6 (2) 00174-2019; 10.1183/23120541.00174-2019
Journal Issue:
April
Disease area:
-
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Clémence Legoupil, Didier Debieuvre, Aurelien Marabelle, Stefan Michiels, Raïssa Kapso, Benjamin Besse, Julia Bonastre. A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. ERJ Open Res, 6 (2) 00174-2019; 10.1183/23120541.00174-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
A non-small cell lung cancer modelling by endogenous κ-ras manipulation
Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection
Year: 2005
Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service
Source: International Congress 2018 – Genetics in chronic pulmonary diseases
Year: 2018
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
Source: Eur Respir Rev 2011; 20: 45-52
Year: 2011
A cost minimisation comparison of five chemotherapy regimes for advanced nonsmall cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 431s
Year: 2003
Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm
Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019
Year: 2020
Assessing the relevance of biological prognostic indices in predicting survival in non-small cell lung cancer
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)?
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003
Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective
Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014
Year: 2014
Identification of predictive biomarkers of immunotherapy response in non-small cell lung cancer by multiparametric analysis
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021
Impacts of multi and specific co-morbidities on the survival of non-surgical non-small cell lung cancer
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer
Source: Eur Respir J 2006; 27: 895-901
Year: 2006
Our experience with crizotinib in the treatment of non-small cell lung cancer
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Second line therapy for advanced non-small cell lung cancer
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Lung function and quality of life after surgical treatment of non-small cell lung cancer – preliminary results
Source: Annual Congress 2008 - Treatment of thoracic tumours
Year: 2008
Effect of comorbidity on the prognosis of non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 385s
Year: 2006
Chemotherapy improves low performance status lung cancer patients
Source: Eur Respir J 2007; 30: 1186-1192
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept